Genistein alters coagulation gene expression in ovariectomised rats treated with phytoestrogens

Thrombosis and Haemostasis

Volumn 104, Issue 6, 2010, Pages 1250-1257

  Kelly, Lynne A ^a   O'Leary, John J ^a   Seidlova Wuttke, Dana ^b   Wuttke, Wolfgang ^b   Norris, Lucy A ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Haemostasis; Menopause; Phytoestrogen; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FIBRINOGEN; FIBRINOGEN ALPHA; FIBRINOGEN BETA; GENISTEIN; MESSENGER RNA; PHYTOESTROGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; GENE EXPRESSION; MENOPAUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT;

ANIMALS; BLOOD COAGULATION; BLOTTING, WESTERN; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN REPLACEMENT THERAPY; FACTOR VII; FEMALE; FIBRINOGEN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENISTEIN; LIVER; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIECTOMY; PHYTOESTROGENS; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR;

EID: 78649733717     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-03-0201     Document Type: Article

References (39)

1. European Heart NetworkEuropean Cardiovascular Disease statistics [Press publication] 2008 [cited December 1, 2009]; Available from: www.ehnheart.org
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321-333.
3. Hsia J, Langer RD, Manson JE, et al. Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative. Arch Intern Med 2006; 166: 357-365. (Pubitemid 43244325)
4. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). J Am Med Assoc 2002; 288: 58-64.
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280: 605-613.
6. Andreana LO, Edward JK. Phytoestrogens: a review of the present state of research. Phytotherapy Res 2003; 17: 845-869.
7. Murkies AL, Wilcox G, Davis SR. Clinical review 92: Phytoestrogens. J Clin Endocrinol Metab 1998; 83: 297-303.
8. Atteritano M, Marini H, Minutoli L, et al. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2007; 92: 3068-3075.
9. Sacks FM, Lichtenstein A, Van Horn L, et al. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006; 113: 1034-1044. (Pubitemid 43879479)
10. Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Thromb Haemost 2007; 97: 558-565.
11. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-3078.
12. Rios DRA, Rodrigues ET, Cardoso APZ, et al. Effects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women. Nutrition 2008; 24: 120-126.
13. Teede HJ, Dalais FS, Kotsopoulos D, et al. Dietary soy containing phytoestrogens does not activate the hemostatic system in postmenopausal women. J Clin Endocrinol Metab 2005; 90: 1936-1941.
14. Trifiletti A, Gaudio A, Lasco A, et al. Haemostatic effects of phytoestrogen genistein in postmenopausal women. Thromb Res 2008; 123: 231-235.
15. Chu MC, Cushman M, Solomon R, et al. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. Am J Obstet Gynecol 2008; 199: 526 e1-7.
16. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139: 4252-4263.
17. Dijsselbloem N, Vanden Berghe W, De Naeyer A, et al. Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. Biochem Pharmacol 2004; 68: 1171-1185.
18. Seidlova-Wuttke D, Hesse O, Jarry H, et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol 2003; 149: 351-362.
19. Seidlova-Wuttke D, Jarry H, Wuttke W. Pure estrogenic effect of benzophenone-2 (BP2) but not of bisphenol A (BPA) and dibutylphtalate (DBP) in uterus, vagina and bone. Toxicology 2004; 205: 103-112.
20. Doerge DR, Chang HC. Inactivation of thyroid peroxidase by soy isoflavones, in vitro and in vivo. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 777: 269-279.
21. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-1532.
22. Lowe GD, Upton MN, Rumley A, et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 2001; 86: 550-556.
23. Hellgren M, Conard J, Norris L, et al. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. Maturitas 2009; 62: 287-293.
24. Ghaddar HM, Folsom AR, Aleksic N, et al. Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. Circulation 1998; 98: 2815-2821.
25. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005; 40: 1215-1220.
26. Soria JM, Almasy L, Souto JC, et al. A Genome Search for Genetic Determinants That Influence Plasma Fibrinogen Levels. Arterioscler Thromb Vasc Biol 2005; 25: 1287-1292.
27. Dalmon J, Laurent M, Courtois G. The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 1993; 13: 1183-1193.
28. Norris LA, Brosnan J, Bonnar J, et al. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone. Thromb Haemost 2008; 100: 253-260.
29. Stevenson JC, Oladipo A, Manassiev N, et al. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004; 124: 802-808.
30. Frohlich J, Steiner G. Dyslipidaemia and coagulation defects of insulin resistance. Int J Clin Pract Suppl 2000: 14-22.
31. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-1221.
32. Devaraj S, Singh U, Jialal I. The Evolving Role of C-Reactive Protein in Atherothrombosis. Clin Chem 2009; 55: 229-238.
33. Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002; 106: 1224-1228.
34. Shifren JL, Rifai N, Desindes S, et al. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 2008; 93: 1702-1710.
35. Rachon D, Suchecka-Rachon K, Hak L, et al. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. Menopause 2006; 13: 840-845.
36. McCarty MF. Isoflavones made simple - Genistein's agonist activity for the betatype estrogen receptor mediates their health benefits. Medical Hypotheses 2006; 66: 1093-1114.
37. Altavilla D, Crisafulli A, Marini H, et al. Cardiovascular effects of the phytoestrogen genistein. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 179-186.
38. Dang ZC. Dose-dependent effects of soy phyto-oestrogen genistein on adipocytes: mechanisms of action. Obes Rev 2009; 10: 342-349.
39. Si H, Liu D. Phytochemical genistein in the regulation of vascular function: new insights. Curr Med Chem 2007; 14: 2581-2589.